| Market Cap | 15.97B | P/E | 21.23 | EPS this Y | 1.30% | Ern Qtrly Grth | 0.10% |
| Income | 601M | Forward P/E | - | EPS next Y | 21.10% | 50D Avg Chg | -1.00% |
| Sales | 3.63B | PEG | 3.11 | EPS past 5Y | - | 200D Avg Chg | - |
| Dividend | 8.00% | Price/Book | 7.15 | EPS next 5Y | 8.52% | 52W High Chg | -28.00% |
| Recommedations | 1.00 | Quick Ratio | 1.01 | Shares Outstanding | 298.07M | 52W Low Chg | 28.00% |
| Insider Own | - | ROA | 7.79% | Shares Float | 49.08M | Beta | 1.08 |
| Inst Own | 0.03% | ROE | 25.81% | Shares Shorted/Prior | -/- | Price | 53.07 |
| Gross Margin | 72.28% | Profit Margin | 16.57% | Avg. Volume | 9,388 | Target Price | 76.45 |
| Oper. Margin | 20.54% | Earnings Date | Nov 19 | Volume | 9,440 | Change | -3.07% |
Sonova Holding AG manufactures and sells hearing care solutions for adults and children in the United States, Europe, the Middle East, Africa, and the Asia Pacific. It operates through two segments, Hearing Instruments and Cochlear Implants segments. The Hearing Instruments segments engages in the design, development, manufacture, distribution, and service of hearing instruments and related products, as well as wireless headsets, speech-enhanced hearables, and audiophile headphones under the Phonak, Unitron, Hansaton, and Sennheiser brand names; and audiological care services under the AudioNova, Audium, Audition Santé, Boots Hearingcare, Connect Hearing, Geers, Hansaton, Lapperre, Schoonenberg, and Triton Hearing brands. The Cochlear Implants segment is involved in the design, development, manufacture, distribution, and service of hearing implants and related products under the Advanced Bionics brand. The company sells its products through independent distributors; and provides hearing care services through a network of stores and clinics. The company was formerly known as Phonak Holding AG and changed its name to Sonova Holding AG in August 2007. The company was founded in 1947 and is headquartered in Stäfa, Switzerland.